BeiGene
BGNE
HK$1,433
Share price
0.49%
Change (1 day)
32.22%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
Earnings for BeiGene (BGNE)
Earnings in 2024 (TTM): -HK$6.82 Billion
According to BeiGene 's latest financial reports the company's current earnings are HK$3.31 Billion. In 2023 the company made an earning of -HK$9.37 Billion, an increase over its 2022 earnings that were of -HK$13.89 Billion. The earnings displayed on this page is the company's Pretax Income.
Earnings history for BeiGene from 2015 to 2024
Annual earnings
| Year | Earnings | Change |
|---|---|---|
2024 (TTM)  | -HK$6.82 Billion | -27.25% |
| 2023 | -HK$9.37 Billion | -32.52% |
| 2022 | -HK$13.89 Billion | 24.39% |
| 2021 | -HK$11.16 Billion | -13.21% |
| 2020 | -HK$12.86 Billion | 72.69% |
| 2019 | -HK$7.45 Billion | 36.01% |
| 2018 | -HK$5.48 Billion | 616.83% |
| 2017 | -HK$0.77 Billion | -15.24% |
| 2016 | -HK$0.91 Billion | 107.91% |
| 2015 | -HK$0.44 Billion |
Earnings for similar companies or competitors
| Company | Earnings | Earnings differencediff. | Country |
|---|---|---|---|
 | -HK$0.15 Billion | -97.92% | 🇺🇸 USA |
 | -HK$80.38 Million | -98.81% | 🇺🇸 USA |